Energenesis Biomedical CO.,LTD. (TPE:6657)
Taiwan · Delayed Price · Currency is TWD 56.50
+0.10 (0.18%)
Aug 1, 2025, 1:30 PM CST
Accolade Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 7.55 | 7.75 | 7.16 | 7.35 | 7.49 | 7.08 | Upgrade | |
Revenue Growth (YoY) | 7.64% | 8.26% | -2.63% | -1.84% | 5.76% | 13.28% | Upgrade |
Cost of Revenue | 1.99 | 2.06 | 1.93 | 2.19 | 2.13 | 2.26 | Upgrade |
Gross Profit | 5.57 | 5.69 | 5.23 | 5.17 | 5.36 | 4.83 | Upgrade |
Selling, General & Admin | 82.37 | 81.01 | 81.94 | 63.14 | 65.69 | 65.98 | Upgrade |
Research & Development | 224.31 | 179.85 | 185.13 | 213.68 | 61.76 | 72.43 | Upgrade |
Operating Expenses | 306.68 | 260.86 | 267.06 | 276.82 | 127.45 | 138.41 | Upgrade |
Operating Income | -301.12 | -255.17 | -261.84 | -271.65 | -122.09 | -133.59 | Upgrade |
Interest Expense | -0.25 | -0.21 | -0.21 | -0.21 | -0.28 | -0.35 | Upgrade |
Interest & Investment Income | 12.26 | 12.51 | 10.44 | 3.93 | 2.41 | 3.41 | Upgrade |
Currency Exchange Gain (Loss) | 3.34 | 11.3 | -8.78 | 2.26 | 0.01 | 0 | Upgrade |
Other Non Operating Income (Expenses) | 0.1 | 0.1 | 0.23 | 0.01 | -0.28 | 1.05 | Upgrade |
EBT Excluding Unusual Items | -285.67 | -231.47 | -260.16 | -265.66 | -120.24 | -129.48 | Upgrade |
Gain (Loss) on Sale of Investments | 0.41 | 0.37 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -0.22 | - | - | - | Upgrade |
Other Unusual Items | - | 0.02 | - | - | - | - | Upgrade |
Pretax Income | -285.26 | -231.08 | -260.38 | -265.66 | -120.24 | -129.48 | Upgrade |
Net Income | -285.26 | -231.08 | -260.38 | -265.66 | -120.24 | -129.48 | Upgrade |
Net Income to Common | -285.26 | -231.08 | -260.38 | -265.66 | -120.24 | -129.48 | Upgrade |
Shares Outstanding (Basic) | 79 | 76 | 72 | 67 | 60 | 59 | Upgrade |
Shares Outstanding (Diluted) | 79 | 76 | 72 | 67 | 60 | 59 | Upgrade |
Shares Change (YoY) | 6.55% | 5.97% | 8.08% | 10.96% | 1.67% | 12.43% | Upgrade |
EPS (Basic) | -3.60 | -3.03 | -3.62 | -3.99 | -2.00 | -2.19 | Upgrade |
EPS (Diluted) | -3.60 | -3.03 | -3.62 | -3.99 | -2.00 | -2.19 | Upgrade |
Free Cash Flow | -236.55 | -181.47 | -225.89 | -239.29 | -106.18 | -103.55 | Upgrade |
Free Cash Flow Per Share | -2.99 | -2.38 | -3.14 | -3.59 | -1.77 | -1.75 | Upgrade |
Gross Margin | 73.67% | 73.43% | 73.02% | 70.26% | 71.56% | 68.14% | Upgrade |
Operating Margin | -3986.21% | -3292.93% | -3657.96% | -3695.47% | -1630.26% | -1886.54% | Upgrade |
Profit Margin | -3776.29% | -2982.06% | -3637.64% | -3613.98% | -1605.50% | -1828.54% | Upgrade |
Free Cash Flow Margin | -3131.47% | -2341.79% | -3155.81% | -3255.16% | -1417.84% | -1462.36% | Upgrade |
EBITDA | -284.69 | -238.69 | -244.58 | -253.78 | -105.63 | -118.11 | Upgrade |
D&A For EBITDA | 16.43 | 16.48 | 17.26 | 17.88 | 16.46 | 15.48 | Upgrade |
EBIT | -301.12 | -255.17 | -261.84 | -271.65 | -122.09 | -133.59 | Upgrade |
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.